• Vision
  • Product
    • CDSS
    • OCS
    • Device
  • Research
    • Disorders
    • Treatment
  • PR
    • Event
    • Patents held
  • About US
    • Neuroen
    • Partner Hospital
  • 한국어
  • Vision
  • Product
    • CDSS
    • OCS
    • Device
  • Research
    • Disorders
    • Treatment
  • PR
    • Event
    • Patents held
  • About US
    • Neuroen
    • Partner Hospital
  • 한국어
2024.12 Global corporate collaboration “Intel AI” results announced

2024.12 Global corporate collaboration “Intel AI” results announced

by neuroen | Feb 1, 2025 | PR EN

2024.12 Global corporate collaboration “Intel AI” results announced “Development of a medical artificial intelligence model for suggesting mental illness treatment using QEEG brain wave test data” (Results...
2024.12 Global Corporate Collaboration “Intel AI” Operator Selected

2024.12 Global Corporate Collaboration “Intel AI” Operator Selected

by neuroen | Feb 1, 2025 | PR EN

2024.12 Global Corporate Collaboration “Intel AI” Operator Selected “Utilizing QEEG EEG Data” Development of a Medical Artificial Intelligence Model for Proposing Treatments for Mental Illnesses (Development of AI...
2023.12 Neuroen Technology Assessment Report “TI-4” Grade

2023.12 Neuroen Technology Assessment Report “TI-4” Grade

by neuroen | Feb 1, 2025 | PR EN

2023.12 Neuroen Technology Assessment Report “TI-4”...
2023.8 Seoul Bio Hub Tenant Selection

2023.8 Seoul Bio Hub Tenant Selection

by neuroen | Feb 1, 2025 | PR EN

2023.8 Seoul Bio Hub Tenant...
2022.10 Samsung Hospital-hosted Digital Health Hackathon Excellence Award

2022.10 Samsung Hospital-hosted Digital Health Hackathon Excellence Award

by neuroen | Feb 1, 2025 | PR EN

2022. 10 Samsung Hospital-hosted Digital Health Hackathon Excellence...
2022.4 Startup Growth R&D Stepping Stone Business Selected

2022.4 Startup Growth R&D Stepping Stone Business Selected

by neuroen | Feb 1, 2025 | PR EN

2022.4 Startup Growth R&D Stepping Stone Business Selected Development of a personalized brain stimulation electronic drug prescription system for mental health...
« Older Entries

최신 글

  • 2024.12 Global corporate collaboration “Intel AI” results announced
  • 2024.12 Global Corporate Collaboration “Intel AI” Operator Selected
  • 2023.12 Neuroen Technology Assessment Report “TI-4” Grade
  • 2023.8 Seoul Bio Hub Tenant Selection
  • 2022.10 Samsung Hospital-hosted Digital Health Hackathon Excellence Award

최신 댓글

No comments to show.

Vision

Product

CDSS
OCS
Device

Research

Disorders

Treatment

PR

주요 Event

보유 특허

About US

기업소개

협력병원 소개

뉴로엔 주식회사

개인정보처리방침 | 이메일무단수집거부 | 문의하기

본사 : 서울특별시 동대문구 회기로 6, 연구실험동 4층 401호
연구소 : 서울특별시 서초구 매헌로 16 하이브랜드 13층 1312호
대표 : 오도연 | 사업자등록번호 : 312-88-01929 | 전화번호 : 033-813-1500

Vision

Product

CDSS
OCS
Device

Research

Disorders

Treatment

PR

주요 Event

보유 특허

About US

기업소개

협력병원 소개

개인정보처리방침 | 문의하기

주식회사 뉴로엔㈜ | 서울특별시동대문구 회기로 117-3 서울바이오하브 연구실험동 401호| CEO : 오도연 | 사업자등록번호 : 312-88-01929
대표전화: T. +82-2-3293-3293 E. brain@neuroen.com (채용/투자 문의 등)
© 2024 Neuroen Inc. All rights reserved.
Copyrightⓒ 2025 Neuroen. All rights reserved.

Contact Us.

본사  / 기업부설 연구소
서울 동대문구 회기로 117-3 서울 바이오 허브 연구실험동 401호
연락처 : 02-3293-3293  / E-Mail 문의 : brain@neuroen.com

Submit your Query